Literature DB >> 24881804

Systemic lupus erythematosus.

Larissa Lisnevskaia1, Grainne Murphy2, David Isenberg3.   

Abstract

Systemic lupus erythematosus is a remarkable and challenging disorder. Its diversity of clinical features is matched by the complexity of the factors (genetic, hormonal, and environmental) that cause it, and the array of autoantibodies with which it is associated. In this Seminar we reflect on changes in its classification criteria; consider aspects of its more serious clinical expression; and provide a brief review of its aetiopathogenesis, major complications, coping strategies, and conventional treatment. Increased understanding of the cells and molecules involved in the development of the diseases has encouraged the identification of new, better targeted biological approaches to its treatment. The precise role of these newer therapies remains to be established.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24881804     DOI: 10.1016/S0140-6736(14)60128-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  209 in total

1.  Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Authors:  Barbora Šumová; Lucie Andrés Cerezo; Lenka Szczuková; Lucie Nekvindová; Michal Uher; Hana Hulejová; Radka Moravcová; Mariam Grigorian; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt; Jakub Závada
Journal:  Rheumatol Int       Date:  2018-11-03       Impact factor: 2.631

2.  Erythropoietin Treatment Ameliorates Lupus Nephritis of MRL/lpr Mice.

Authors:  Zeming Zhang; Dongmei Liu; Xiaoli Zhang; Xiaofei Wang
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

3.  Lupus and proliferative nephritis are PAD4 independent in murine models.

Authors:  Rachael A Gordon; Jan M Herter; Florencia Rosetti; Allison M Campbell; Hiroshi Nishi; Michael Kashgarian; Sheldon I Bastacky; Anthony Marinov; Kevin M Nickerson; Tanya N Mayadas; Mark J Shlomchik
Journal:  JCI Insight       Date:  2017-05-18

4.  FcγRIIb on CD11c+ cells modulates serum cholesterol and triglyceride levels and differentially affects atherosclerosis in male and female Ldlr-/- mice.

Authors:  Jennifer Marvin; Jillian P Rhoads; Amy S Major
Journal:  Atherosclerosis       Date:  2019-04-13       Impact factor: 5.162

5.  Is osteonecrosis due to systemic lupus erythematosus associated with increased risk of complications following total hip arthroplasty?

Authors:  Dennis Q Chen; Jourdan M Cancienne; Brian C Werner; Quanjun Cui
Journal:  Int Orthop       Date:  2018-03-17       Impact factor: 3.075

Review 6.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

7.  Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.

Authors:  Jing Wang; Yuan-Yuan Qi; Xue-Ping Chen; Li Ma; Li-Li Zhang; Yu Zhao; Mei Wang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

8.  Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.

Authors:  Ahmed Nader; Mukul Minocha; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

Review 9.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.